225 related articles for article (PubMed ID: 9420390)
21. The efficacy of intravenous pulse cyclophosphamide in the treatment of severe lupus nephritis in children.
Tangnararatchakit K; Tapaneya-Olarn C; Tapaneya-Olarn W
J Med Assoc Thai; 1999 Nov; 82 Suppl 1():S104-10. PubMed ID: 10730528
[TBL] [Abstract][Full Text] [Related]
22. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy.
Ponticelli C; Altieri P; Scolari F; Passerini P; Roccatello D; Cesana B; Melis P; Valzorio B; Sasdelli M; Pasquali S; Pozzi C; Piccoli G; Lupo A; Segagni S; Antonucci F; Dugo M; Minari M; Scalia A; Pedrini L; Pisano G; Grassi C; Farina M; Bellazzi R
J Am Soc Nephrol; 1998 Mar; 9(3):444-50. PubMed ID: 9513907
[TBL] [Abstract][Full Text] [Related]
23. Application of artificial neural networks in estimating predictive factors and therapeutic efficacy in idiopathic membranous nephropathy.
Naumovic R; Furuncic D; Jovanovic D; Stosovic M; Basta-Jovanovic G; Lezaic V
Biomed Pharmacother; 2010 Nov; 64(9):633-8. PubMed ID: 20888177
[TBL] [Abstract][Full Text] [Related]
24. Short- and long-term efficacy of oral cyclophosphamide and steroids in patients with membranous nephropathy and renal insufficiency. Study Group.
Branten AJ; Wetzels JF
Clin Nephrol; 2001 Jul; 56(1):1-9. PubMed ID: 11499653
[TBL] [Abstract][Full Text] [Related]
25. EULAR randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis.
Yee CS; Gordon C; Dostal C; Petera P; Dadoniene J; Griffiths B; Rozman B; Isenberg DA; Sturfelt G; Nived O; Turney JH; Venalis A; Adu D; Smolen JS; Emery P
Ann Rheum Dis; 2004 May; 63(5):525-9. PubMed ID: 15082482
[TBL] [Abstract][Full Text] [Related]
26. Compared clinical efficacy and bone metabolic effects of low-dose deflazacort and methyl prednisolone in male inflammatory arthropathies: a 12-month open randomized pilot study.
Saviola G; Abdi Ali L; Shams Eddin S; Coppini A; Cavalieri F; Campostrini L; Sacco S; Bucci M; Cirino G; Rossini M
Rheumatology (Oxford); 2007 Jun; 46(6):994-8. PubMed ID: 17384176
[TBL] [Abstract][Full Text] [Related]
27. Monthly pulses of methylprednisolone in SLE nephritis.
Liebling MR; McLaughlin K; Boonsue S; Kasdin J; Barnett EV
J Rheumatol; 1982; 9(4):543-8. PubMed ID: 7131454
[TBL] [Abstract][Full Text] [Related]
28. [Comparison of two cyclophosphamide treatment regimens in nephrotic patients with chronic glomerulonephritis].
Krasnova TN; Shilov EM; Tareeva IE; Gordovskaia NB; Lavrova ON; Miroshnichenko NG; Troepol'skaia OV; Ivanova LV; Ivanov AA
Ter Arkh; 1998; 70(6):14-7. PubMed ID: 9695216
[TBL] [Abstract][Full Text] [Related]
29. [Effects of methylprednisolone pulse therapy in the insidious type of crescentic glomerulonephritis].
Takeda S; Kida H; Takazakura E; Yokoyama H; Kobayashi K
Nihon Jinzo Gakkai Shi; 1997 Jul; 39(5):490-6. PubMed ID: 9379560
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of steroids, cyclosporin and cyclophos-phamide in steroid resistant idiopathic nephrotic syndrome.
Hafeez F; Ahmad TM; Anwar S
J Coll Physicians Surg Pak; 2005 Jun; 15(6):329-32. PubMed ID: 15924835
[TBL] [Abstract][Full Text] [Related]
31. Clinical and morphologic evolution of idiopathic membranous nephropathy.
Zucchelli P; Cagnoli L; Pasquali S; Casanova S; Donini U
Clin Nephrol; 1986 Jun; 25(6):282-8. PubMed ID: 3524923
[TBL] [Abstract][Full Text] [Related]
32. A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy.
Ponticelli C; Zucchelli P; Passerini P; Cesana B; Locatelli F; Pasquali S; Sasdelli M; Redaelli B; Grassi C; Pozzi C
Kidney Int; 1995 Nov; 48(5):1600-4. PubMed ID: 8544420
[TBL] [Abstract][Full Text] [Related]
33. Intratympanic methylprednisolone for sudden sensorineural hearing loss.
Kiliç R; Safak MA; Oğuz H; Kargin S; Demirci M; Samim E; Ozlüoğlu LN
Otol Neurotol; 2007 Apr; 28(3):312-6. PubMed ID: 17414035
[TBL] [Abstract][Full Text] [Related]
34. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia.
Knauf WU; Lissichkov T; Aldaoud A; Liberati A; Loscertales J; Herbrecht R; Juliusson G; Postner G; Gercheva L; Goranov S; Becker M; Fricke HJ; Huguet F; Del Giudice I; Klein P; Tremmel L; Merkle K; Montillo M
J Clin Oncol; 2009 Sep; 27(26):4378-84. PubMed ID: 19652068
[TBL] [Abstract][Full Text] [Related]
35. Complete remission of nephrotic syndrome after steroid-chlorambucil in a previous failed short-term steroidal treatment of a primary membranous nephropathy.
Ardiles LG; Mezzano SA
Clin Nephrol; 1996 Jun; 45(6):423. PubMed ID: 8793243
[No Abstract] [Full Text] [Related]
36. Conservative treatment of primary gastric low-grade B-cell lymphoma of mucosa-associated lymphoid tissue: predictive factors of response and outcome.
Levy M; Copie-Bergman C; Traulle C; Lavergne-Slove A; Brousse N; Flejou JF; de Mascarel A; Hemery F; Gaulard P; Delchier JC;
Am J Gastroenterol; 2002 Feb; 97(2):292-7. PubMed ID: 11866264
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of a second course of immunosuppressive therapy in patients with membranous nephropathy and persistent or relapsing disease activity.
du Buf-Vereijken PW; Wetzels JF
Nephrol Dial Transplant; 2004 Aug; 19(8):2036-43. PubMed ID: 15187191
[TBL] [Abstract][Full Text] [Related]
38. Treatment-related changes in urinary excretion of high and low molecular weight proteins in patients with idiopathic membranous nephropathy and renal insufficiency.
du Buf-Vereijken PW; Wetzels JF
Nephrol Dial Transplant; 2006 Feb; 21(2):389-96. PubMed ID: 16234291
[TBL] [Abstract][Full Text] [Related]
39. The effectiveness of steroid therapy for patients with advanced IgA nephropathy and impaired renal function.
Moriyama T; Honda K; Nitta K; Yumura W; Nihei H
Clin Exp Nephrol; 2004 Sep; 8(3):237-42. PubMed ID: 15480901
[TBL] [Abstract][Full Text] [Related]
40. Corticosteroids and ciclosporin A in idiopathic membranous nephropathy: higher remission rates of nephrotic syndrome and less adverse reactions than after traditional treatment with cytotoxic drugs.
Goumenos DS; Katopodis KP; Passadakis P; Vardaki E; Liakopoulos V; Dafnis E; Stefanidis I; Vargemezis V; Vlachojannis JG; Siamopoulos KC
Am J Nephrol; 2007; 27(3):226-31. PubMed ID: 17389782
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
